Entrada Therapeutics TRDA
NASDAQ TRDA
$6.26 +0.04 (+0.64%)
At close: Sep 29, 2026 · 4:00 PM EDT

Entrada Therapeutics (TRDA) Research & Development (2020 - 2026)

Updated

Entrada Therapeutics' Research & Development was $35.37 million in Q2 2026, down 6.6% from $37.88 million a year earlier but up 7.0% from the prior quarter.

Analysis

Entrada Therapeutics (TRDA) Research & Development (2020 - 2026) Analysis & Trends

On a trailing twelve-month basis, Entrada Therapeutics' Research & Development was $140.74 million through Jun 30, 2026, up 4.6% year-over-year; for FY2025, it was $142.27 million, up 13.5% from FY2024.

  • Research & Development has now increased for five consecutive years, with a five-year compound annual growth rate of 46.5% (FY2020 to FY2025).
  • In earlier years, Research & Development was $125.31 million in FY2024 (+25.5%), $99.88 million in FY2023 (+50.0%), $66.61 million in FY2022 (+85.4%) and $35.93 million in FY2021 (+70.2%).
  • Quarterly Research & Development has moved between $10.51 million (Q3 2021) and $38.36 million (Q3 2025) over five years.
  • Compared with a year earlier, Research & Development was higher in seven of the last eight quarters, with growth averaging 13.8%.
  • The best year-over-year quarter for Research & Development over five years was Q1 2022 (growth of 152.6%); the worst was Q2 2026 (a decline of 6.6%).
  • Per Business Quant data, TRDA's Research & Development in the three quarters before Q2 2026 was $33.05 million (Q1 2026), $33.96 million (Q4 2025) and $38.36 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 3.65 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 2.34 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 9.74 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn -2.85 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn -4.05 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 1.87 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn 1.76 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 2.81 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn 993.80 Mn
10 Entrada Therapeutics 242.19 Mn 242.19 Mn - 35.37 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 35.37 Mn
Mar 31, 2026 33.05 Mn
Dec 31, 2025 33.96 Mn
Sep 30, 2025 38.36 Mn
Jun 30, 2025 37.88 Mn
Mar 31, 2025 32.07 Mn
Dec 31, 2024 33.41 Mn
Sep 30, 2024 31.26 Mn
Jun 30, 2024 32.04 Mn
Mar 31, 2024 28.61 Mn
Dec 31, 2023 28.29 Mn
Sep 30, 2023 22.19 Mn
Jun 30, 2023 26.30 Mn
Mar 31, 2023 23.10 Mn
Dec 31, 2022 15.69 Mn
Sep 30, 2022 18.96 Mn
Jun 30, 2022 16.25 Mn
Mar 31, 2022 15.72 Mn
Dec 31, 2021 12.36 Mn
Sep 30, 2021 10.51 Mn
API Access

Entrada Therapeutics Research & Development API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=research-and-development&ticker=TRDA&period=max&api_key=YOUR_API_KEY